Market Overview

FBR Capital Upgrades AMAG Pharmaceuticals To Outperform

Related AMAG
A Peek Into The Markets: U.S. Stock Futures Mostly Up Ahead Of Labor Market Conditions Index
Your Cheat Sheet For Q1 Biotech Earnings

Analysts at FBR Capital upgraded AMAG Pharmaceuticals (NASDAQ: AMAG) from Market Perform to Outperform.

The target price for AMAG Pharmaceuticals has been raised from $21 to $36.

AMAG Pharmaceuticals shares have surged 36.08% over the past 52 weeks, while the S&P 500 index has gained 16.68% in the same period.

AMAG Pharmaceuticals' shares jumped 28.21% to close at $29.72 yesterday.

Latest Ratings for AMAG

Feb 2017Cowen & Co.DowngradesOutperformMarket Perform
Jan 2017Raymond JamesDowngradesMarket PerformUnderperform
Jan 2017Janney CapitalInitiates Coverage OnBuy

View More Analyst Ratings for AMAG
View the Latest Analyst Ratings

Posted-In: FBR CapitalUpgrades Analyst Ratings


Related Articles (AMAG)

View Comments and Join the Discussion!